ClinicalTrialsFinder
RecruitingNCT06665776

HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

A Prospective Observational Human Subject Research to Explore the HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

Sponsor

PharmaEssentia

Enrollment

1,200 participants

Start Date

Mar 14, 2023

Study Type

OBSERVATIONAL

Conditions

Solid Tumor Malignancy

Summary

This is a prospective observational research to explore the frequency of Human leukocyte antigen A allele 02:01 (HLA\*02:01) and the expression status of New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in cancer patients in Taiwanese population.

Eligibility

Min Age: 18 Years

Inclusion Criteria16

  • Able to understand and voluntarily sign an informed consent form (ICF).
  • Adult aged ≥ 18 years at the time of informed consent (or other age required by local regulations).
  • Confirmed diagnosis of any of the following solid tumor:
  • Head and neck squamous cell carcinoma, excluding nasopharyngeal carcinoma;
  • Hepatocellular carcinoma;
  • Lung squamous cell carcinoma;
  • Synovial sarcoma;
  • Triple-negative breast cancer;
  • Esophageal squamous cell carcinoma;
  • Cervical cancer;
  • Ovarian cancer
  • Patient who received standard curative or palliative therapy including but not limited to any targeted therapy based on mutation status for their cancer, or patient with advanced solid tumors for which there is no accepted therapy, standard therapies are no longer effective, or the patient refuses additional standard therapy.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1.
  • Body weight ≥ 50 Kg.
  • Life expectancy of ≥ 6 months.
  • Patient who agrees to provide the tumor sample for NY-ESO-1 IHC staining, from either fresh or archival tissue

Exclusion Criteria6

  • Known primary immunodeficiency (such as Severe Combined Immunodeficiency Disease or AIDS).
  • Uncontrolled intercurrent illness which is not suitable for enrollment at the discretion of the investigator, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements.
  • Currently confirmed diagnosis of at least 2 active cancers; patient who was cured of the other cancer \[disease free period > 6 months\] and currently has only one research targeted tumor can be enrolled.
  • Untreated or symptomatic brain metastasis.
  • History of organ transplantation or allogeneic stem cell transplantation.
  • Other conditions (e.g. previous use of any cell therapy) which are not suitable for enrollment at the discretion of the investigator.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(6)

Chang Gung Memorial Hospital, Chiayi Branch

Chiayi City, Taiwan, Taiwan

Taichung Veterans General Hospital

Taichung, Taiwan, Taiwan

National Cheng Kung University Hospital

Tainan, Taiwan, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan, Taiwan

National Taiwan University Hospital

Taipei, Taiwan, Taiwan

Taipei Medical University Hospital

Taipei, Taiwan, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06665776

Related Trials

Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients

NCT069114892 locations

A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients

NCT069853681 location

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

NCT057682697 locations